<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04868227</url>
  </required_header>
  <id_info>
    <org_study_id>2014/0058</org_study_id>
    <nct_id>NCT04868227</nct_id>
  </id_info>
  <brief_title>Scottish Vitamin D Intervention Study</brief_title>
  <acronym>(SCoViDS)</acronym>
  <official_title>Scottish Vitamin D Intervention Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AIMS To identify the underlying mechanism by which Vitamin D reduces colorectal cancer risk.&#xD;
&#xD;
      OBJECTIVES To demonstrate the effects of vitamin D supplementation on serum vitamin D levels.&#xD;
&#xD;
      To demonstrate dynamic changes in gene expression in response to vitamin D. To demonstrate&#xD;
      the mechanism underlying the gene-environment interaction of vitamin D, susceptibility&#xD;
      genetic variants (risk genes) and colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Through National Health Service (NHS) clinical services in colorectal surgery and oncology,&#xD;
      patients will be identified and recruited from surgical wards or surgical/oncology&#xD;
      out-patient clinics. A sample of participants with and without a new or previous diagnosis of&#xD;
      colorectal cancer will be included for comparison.&#xD;
&#xD;
      Participation will consist of two events in the majority of participants. Firstly a in the&#xD;
      surgical ward or clinic lasting no longer than 20 minutes in which the research will be&#xD;
      discussed and informed consent gained. A blood sample will be taken prior to the conclusion&#xD;
      of recruitment and a rectal biopsy taken using a rigid sigmoidoscopy which may or may not be&#xD;
      required as part of their routine clinical assessment. Participants will be asked to take&#xD;
      pharmaceutical grade vitamin D tablets for 3 months. After 12 weeks of vitamin D&#xD;
      supplementation, a final blood sample and rectal biopsy will be taken.&#xD;
&#xD;
      If patients would like to contribute but cannot or would prefer not to take vitamin D, or&#xD;
      cannot return for future sampling, a single sampling will be offered. This participant would&#xD;
      undergo blood sampling and rectal biopsy as above. After this no further events would occur.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 28, 2014</start_date>
  <completion_date type="Actual">July 11, 2016</completion_date>
  <primary_completion_date type="Actual">April 11, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>SINGLE GROUP INTERVENTION STUDY</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GENE EXPRESSION</measure>
    <time_frame>AT BASELINE</time_frame>
    <description>RECTAL MUCOSA GENE EXPRESSION</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GENE EXPRESSION CHANGE</measure>
    <time_frame>AFTER 6 WEEK'S SUPPLEMENTATION</time_frame>
    <description>RECTAL MUCOSA GENE EXPRESSION</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GENE EXPRESSION CHANGE</measure>
    <time_frame>AFTER 12 WEEK'S SUPPLEMENTATION</time_frame>
    <description>RECTAL MUCOSA GENE EXPRESSION</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VITAMIN D STATUS</measure>
    <time_frame>AT BASELINE</time_frame>
    <description>25-hydroxy-vitamin D (25-OHD) level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VITAMIN D STATUS CHANGE</measure>
    <time_frame>AFTER 6 WEEK'S SUPPLEMENTATION</time_frame>
    <description>25-hydroxy-vitamin D (25-OHD) level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VITAMIN D STATUS CHANGE</measure>
    <time_frame>AFTER 12 WEEK'S SUPPLEMENTATION</time_frame>
    <description>25-hydroxy-vitamin D (25-OHD) level</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>GENE EXPRESSION</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>INTERVENTION STUDY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TREATED WITH 3200IU FULTIUM VITAMIN D3</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>FULTIUM D3 VITAMIN D3</intervention_name>
    <description>VITAMIN D3 SUPPLEMENT</description>
    <arm_group_label>INTERVENTION STUDY</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 16 years or over.&#xD;
&#xD;
          -  Resident of the United Kingdom&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The inability to provide informed consent.&#xD;
&#xD;
          2. Under the age of 16 years.&#xD;
&#xD;
          3. A non-UK resident.&#xD;
&#xD;
          4. Patients who may be at increased risk from rigid sigmoidoscopy:&#xD;
&#xD;
               -  Individuals who are taking anti-coagulation medication.&#xD;
&#xD;
               -  Individuals with platelet disease or other bleeding issues.&#xD;
&#xD;
               -  Individuals with a history of a significant rectal bleed.&#xD;
&#xD;
               -  Suspected or known bowel perforation&#xD;
&#xD;
               -  Anal stenosis&#xD;
&#xD;
               -  Acute peritonitis&#xD;
&#xD;
               -  Colonic necrosis&#xD;
&#xD;
               -  Toxic megacolon&#xD;
&#xD;
               -  Acute severe diverticulitis&#xD;
&#xD;
               -  Diverticular abscess&#xD;
&#xD;
               -  Recent colonic surgery&#xD;
&#xD;
               -  Anal fissure&#xD;
&#xD;
               -  Severe coagulopathy&#xD;
&#xD;
               -  Anticoagulant therapy&#xD;
&#xD;
               -  Severe thrombocytopenia&#xD;
&#xD;
               -  Severe neutropenia&#xD;
&#xD;
          5. Patients who may be at increased risk from Vitamin D supplementation would not be&#xD;
             included in the intervention arm but could still be included in the single sample arm:&#xD;
&#xD;
               -  Kidney disease&#xD;
&#xD;
               -  High levels of calcium in the blood&#xD;
&#xD;
               -  Atherosclerosis&#xD;
&#xD;
               -  Sarcoidosis&#xD;
&#xD;
               -  Histoplasmosis&#xD;
&#xD;
               -  Over-active parathyroid gland (hyperparathyroidism)&#xD;
&#xD;
               -  Lymphoma&#xD;
&#xD;
               -  Currently taking thiazide diuretics, digoxin or other cardiac glycosides&#xD;
&#xD;
               -  Known allergy to nuts ( as peanut oil contained within vitamin D preparations)&#xD;
&#xD;
               -  Female subjects of child bearing age who are not taking effective contraception&#xD;
                  during the period of the trial&#xD;
&#xD;
          6. Patients in whom vitamin D levels may be unpredictable&#xD;
&#xD;
               -  Individuals already established on supplementary Vitamin D.&#xD;
&#xD;
               -  Individuals recently returned to the UK from an overseas holiday.&#xD;
&#xD;
               -  Individuals who have recently lived abroad.&#xD;
&#xD;
               -  Patients on anti-epileptic medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm G Dunlop, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MRC HGU University of Ediniburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH42XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/geo/</url>
    <description>GEO ID GSE157982.</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 25, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VITAMIN D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Transcript profiling: Available at https://www.ncbi.nlm.nih.gov/geo/ Gene Expression Omnibus (GEO) identifier (ID) GSE157982. Full phenotypic data available from the corresponding author on reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>AS REQUESTED</ipd_time_frame>
    <ipd_access_criteria>Full protocol and Full phenotypic data available from the corresponding author on reasonable request.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

